Board of Directors

John D. Diekman, Ph.D.

Chairman of the Board | Founding Partner, 5AM Ventures

John D. Diekman, Ph.D. is a Founding Partner of 5AM Ventures. Previously Dr. Diekman was Chairman and CEO of Affymetrix, and Chairman and Managing Director of Affymax. Dr. Diekman currently serves as Chairman of IDEAYA as well as on the Boards of Igenica and Wildcat. He is a Charter Trustee of Princeton University and a former Trustee of the California Institute of Technology and of the Scripps Research Institute, where he served as Chairman. He serves on the Schaeffer Center for Health Policy and Economics Advisory Board at the University of Southern California. He is an Honorary Officer of the Order of Australia. Dr. Diekman received a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University. Dr. Diekman holds an Honorary Degree of Doctor of Laws from Monash University.

Timothy Shannon, M.D.

Director | General Partner, Canaan Partners

Timothy Shannon, M.D., is a General Partner at Canaan Partners where he focuses on early stage biopharmaceutical companies. He is chairman of the board of Arvinas and Spyryx Therapeutics and is a director at NextCure, Vivace, and CytomX (CTMX, IPO 2015). Prior successful companies include Civitas Theraputics (acquired by Acorda) and Novira Therapeutics (acquired by Johnson & Johnson). Dr. Shannon previously was president and chief executive officer of CuraGen, a publically traded biopharmaceutical company. CuraGen merged with Celldex Therapeutics in 2009 where Dr. Shannon served on the board. Prior to that he was senior vice president of global medical development for Bayer’s Pharmaceutical Business Group. Dr. Shannon began his career as an assistant professor of pulmonary and critical care medicine at Yale University School of Medicine, received his M.D. from the University of Connecticut, and his B.A. from Amherst College.

Terry Rosen, Ph.D.

Director | Chief Executive Officer, Arcus Biosciences

Terry Rosen, Ph.D. is currently the CEO of Arcus Biosciences. He previously served as CEO of Flexus Biosciences, which was acquired by BMS in 2015. Prior to co-founding Flexus in October of 2013, Terry served as Vice President, Therapeutic Discovery (TD) at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. Terry held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. Terry serves on the Salk Institute Board of Trustees, the leadership committees of the University of Michigan Undergraduate Research Opportunity Program and Life Sciences Institute, the Berkeley Chemistry Advisory Board, the Caltech Biology and Biology and Biological Engineering Chair’s Council and the California Life Sciences Association Board. He holds a B.S. in Chemistry from the University of Michigan and a Ph.D. in Organic Chemistry from the University of California, Berkeley.

Jeffrey Stein, Ph.D.

Director | President and Chief Executive Officer, Cidara Therapeutics

Jeffrey Stein, Ph.D., has been the President and Chief Executive Officer of Cidara Therapeutics since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September of 2013. Dr. Stein was also the founding Chairman and President of the Antibiotics Working Group. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm’s San Diego office in 2005. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at UCSD.

Brian Daniels, M.D.

Director | Former SVP, Global Development and Medical Affairs, Bristol-Myers Squibb

Brian Daniels, M.D., served as Senior Vice President of Global Development and Medical Affairs and Research and Development of Bristol-Myers Squibb Co. from March 2008 to July 1, 2014. He served as Senior Vice President of Global Clinical Development, Research and Development of Bristol-Myers Squibb Co. from 2004 to 2008. He also served as a Member of Management Council at Bristol-Myers Squibb Company. He held positions directing and conducting clinical research at Merck and Genentech. He directed the development of innovative medicines, including Apixaban®, Onglyza®, Myalept® and Farxiga® (CV/metabolics), Orencia® and Nulogix® (immunology), Abilify® (neuroscience), Baraclude®, Reyataz®, Daclatasvir® and Asunaprevir® (virology) and Sprycel®, Ixempra®, Yervoy®, elotuzumab and nivolumab (oncology). He serves on the Board of Directors of Novo Nordisk, among others. He completed residency programs at The New York Hospital of Cornell Medical College and at UCSF. Dr. Daniels has an M.D. from Washington University and an M.S. and B.S. from MIT.

Thilo Schroeder, Ph.D.

Director | Partner at Nextech Invest

Thilo Schroeder, Ph.D. is Partner at Nextech Invest Ltd., a global venture fund focused on investing in leading oncology companies. Prior to joining Nextech Invest in 2012, Dr. Schroeder worked in research specializing on the development of Designed Ankyrin Repeat Proteins (DARPins) as specific protein inhibitors (licensed to Molecular Partners / SWX:MOLN). He acquired expertise in molecular biology as an Intern at Micromet Ltd. (now Amgen) and during his studies at the University of Sydney. Dr. Schroeder currently serves as board member of Revolution Medicines, IDEAYA Bioscience, ImaginAb and board observer of Peloton Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ:BPMC), SiROP Global, and board observer of Tracon Pharmaceuticals (NASDAQ:TCON). He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.

Edward Hu, Ph.D.

Director | Founding Partner, WuXi Healthcare Ventures, Founding Partner, 6 Dimensions Capital, CFO and CIO, WuXi AppTec 

Edward Hu, Ph.D., M.B.A. is currently CFO and CIO at WuXi AppTec, and Partner at WuXi Healthcare Ventures and 6 Dimensions Capital. Mr. Hu manages the company’s finance, investments, mergers and acquisitions, joint ventures, and new business and capability building. In addition, Mr. Hu oversees WuXi Healthcare Ventures’ investment activities and portfolio management. Mr. Hu previously served as WuXi’s COO and CFO until April 2014. Prior to joining WuXi in August 2007, Mr. Hu was SVP and COO at Tanox, responsible for operations, finance, IT, project management and strategic planning, and managed the acquisition of Tanox by Genentech in 2007. He also held positions at Merck & Co., Inc. as a Senior Financial Analyst and later in Business and Financial Planning at Biogen, Inc., where he managed the business planning of Biogen’s R&D and clinical operations organizations, and provided project planning and analysis support to key drug development project teams. Mr. Hu completed his Ph.D. work, all but dissertation, in Biophysics and Biochemistry at Carnegie Mellon University, where he also received his M.B.A.

Scott Morrison

Director | Partner, Ernst & Young (retired)

Mr. Morrison has served as a member of IDEAYA’s board of directors since July 2018. He had a 35-year career in public accounting, serving public and private companies in the life sciences sector. Mr. Morrison was a partner at Ernst & Young LLP and served as its U.S. Life Sciences Leader until his retirement in 2015. He has worked on hundreds of public and private financings, M&A transactions and corporate collaborations. Mr. Morrison currently serves on the board of directors and chairs the audit committees of Audentes Therapeutics, Corvus Pharmaceuticals, Global Blood Therapeutics and Symic Bio. He has served on numerous life sciences industry boards, including the Biotechnology Innovation Organization (BIO) ECS Board, the Bay Area Bioscience Center, the California Life Sciences Foundation, and the Biotechnology Institute. Mr. Morrison holds a B.S. in business administration from the University of California, Berkeley. He is a certified public accountant (inactive).

Yujiro S. Hata

Director | Chief Executive Officer, IDEAYA Biosciences

Yujiro is an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients. In August 2015, he launched IDEAYA Biosciences as its first employee and Chief Executive Officer, while serving as an Executive-in-Residence at 5AM Ventures from 2015 to 2018. From 2014 to August 2015, he served as Chief Operating Officer at Flexus Biosciences and FLX Bio, which he joined as a startup and led through its acquisition by Bristol-Myers Squibb in April 2015. From 2010 through the approvals of Kyprolis® and Stivarga® and its acquisition by Amgen in October 2013, he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals (NASDAQ: ONXX), where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010, Yujiro served as Vice President, Senior Vice President, and Chief Business Officer at Enanta Pharmaceuticals (NASDAQ: ENTA), which he joined as a startup and helped build to a public company that discovered the protease inhibitors contained in Viekira Pak and Mavyret™, both of which received Breakthrough Therapy designation by the U.S. FDA. He earlier served in roles at McKinsey, ImClone and Columbia Medical School.

Yujiro obtained his MBA at Wharton as a Henry J Kaiser recipient and did undergraduate studies at Oxford University and Colorado College. He serves on the Board of Directors at Xencor (NASDAQ: XNCR) and Expansion Therapeutics, and Board of Visitors at the UCSD Cancer Center.

Kanishka Pothula

Board Observer | Managing Director at BVF Partners

Kanishka Pothula is Managing Director at BVF Partners L.P., a San Francisco-based investment firm focused on public and private life science companies. He currently serves on the board of Relay Therapeutics. Mr. Pothula joined BVF in 2012. Prior to joining BVF, Mr. Pothula was an Associate at BroadOak Capital Partners, a life sciences focused investment bank. Prior to BroadOak, he worked as a Research Associate at the University of California, San Diego’s Medical School conducting primary research on apoptotic modeling on T-lymphoma cancer cells. Mr. Pothula holds an M.S. in Biotechnology from Georgetown University and a B.S. in Bioengineering from the University of California, San Diego.

Vineeta Agarwala, M.D., Ph.D.

Board Observer | Venture Partner at GV

Vineeta Agarwala, M.D., Ph.D., is a physician-scientist who is passionate about the intersection of biology, data science, and medicine. As a director of product management at Flatiron Health, she led development of national-scale databases that integrate real-world clinical and genomic data for drug development and research in oncology. Previously, Vineeta was at the Broad Institute, where she analyzed large human sequencing datasets to characterize the genetic basis of common human diseases. Vineeta has also been a computational researcher at Cold Spring Harbor Laboratory and Lawrence Livermore National Laboratory, and a management consultant for biotech and pharmaceutical clients at McKinsey & Company in New York. She holds a B.S. in biophysics from Stanford University, and earned M.D./Ph.D. degrees from Harvard Medical School and MIT. She is currently a Venture Partner focused on life sciences at GV.

Nisha Marathe, Ph.D.

Board Observer | Investment Analyst at Roche Venture Fund

Nisha Marathe, Ph.D., joined the Roche Venture Fund in 2016. Prior to RVF, she was an associate with Mission Bay Capital and Business Manager at QB3@953, a life-sciences incubator based in San Francisco. Dr. Marathe completed her post-doctoral training at UCSF where she also worked as a Technology Analyst with the Office of Technology Management. She holds a Ph.D. from UCSD in Molecular and Cell Biology and received her B.S. from UCLA, graduating cum laude and with College Honors.

Peter Worland, Ph.D.

Board Observer | Corporate Vice President, Integrative Research Development, Celgene

Peter Worland, Ph.D., is currently Corporate Vice President of Integrative Research Development at Celgene where he identifies collaborations (academic and corporate) that extend the reach of Celgene’s internal research programs and development pipeline. He has been integral to creating numerous collaborations over the last 9 years at Celgene and is continually working to maximize the value of existing partnerships and identify new potential partnerships complementing the Celgene strategic plan. Prior to this, Peter had responsibility for Experimental Therapeutics within the Discovery group. Prior to joining Celgene, Peter ran the Discovery Oncology effort at Millennium, led Discovery programs at Pharmacia and managed academic collaborations at the European Institute of Oncology, Milan and built the Pharmacology group and led Discovery programs at Mitotix in Cambridge, MA. After completing his Ph.D. in the Clinical Pharmacology Unit, Department of Medicine, University of Melbourne, Australia, Peter worked as a Visiting Scientist at the NCI for a number of years before entering industry.

Mira Chaurushiya, Ph.D.

Board Observer | Senior Associate at 5AM Ventures

Mira Chaurushiya, Ph.D. is a Senior Associate at 5AM Ventures. Dr. Chaurushiya joined in 2015 from Genentech where she was a Postdoctoral Fellow in the Department of Physiological Chemistry studying mouse models of cancer and stem cells. Prior to Genentech, she completed her Ph.D. work at the Salk Institute, where she studied Herpes Simplex Virus infections and epigenetics. Her work has been published in Science and PNAS, among others. Dr. Chaurushiya currently serves as an Observer on the Boards of Precision Nanosystems, Biodesy, Purigen Biosystems, Escient Pharmaceuticals, Chrono Therapeutics, and Ideaya Biosciences. In addition, she is a Fellow of the Society of Kauffman Fellows and serves on the Board of Biotech Connection Bay Area, a non-profit that focuses on career development for academic scientists. Dr. Chaurushiya received a Ph.D. in Biological Sciences from the University of California, San Diego in conjunction with the Salk Institute for Biological Studies, where she was awarded the Martin Kamen Thesis Prize in Biochemistry. She received her B.A. in Biology from Carleton College.